ArticleIJID regions2025
Phase-wise comparison of depression and stigma among tuberculosis patients undergoing treatment in Dhaka, Bangladesh.
Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Depressive symptoms and their associations with tuberculosis-related knowledge, attitudes, and practices among patients with multidrug-resistant tuberculosis.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Tuberculosis (TB) remains a significant global health concern with established links to depression and stigma. Both outcomes have been found to vary between treatment phases of TB. This study compared depression and stigma among patients with TB in the intensive and continuation treatment phases in Dhaka, Bangladesh. Methods: A cross-sectional comparative study was conducted during August and September 2023 among 111 patients in the intensive phase and 113 in the continuation phase of TB treatment (a total of 224) at directly observed treatment short-course centers. Depression was assessed using the Patient Health Questionnaire-9, and stigma was measured using Van Rie's TB/HIV Stigma Scale. Multivariable logistic regression identified associated factors. Results: The prevalence of depression was 56.2% overall, with no significant difference between the intensive (59.5%) and continuation phases (53.1%). Anticipated stigma was more prevalent (74.6%) than social stigma (37.5%), with neither showing significant phase variation. Pulmonary TB was associated with both social stigma (odds ratio [OR] = 3.27, 95% confidence interval [CI]: 1.69-6.52) and anticipated stigma (OR = 3.29, 95% CI: 1.70-6.59). Living with family increased the odds of experiencing anticipated stigma, while patient counseling demonstrated protective effects. Depression was associated with treatment adherence difficulties (OR = 3.55, 95% CI: 1.75-7.51), persistent TB symptoms (OR = 2.23, 95% CI: 1.04-4.91), and social stigma (OR = 2.06, 95% CI: 1.02-4.22). Conclusions: The high prevalence of depression and persistent stigma throughout treatment highlight the need for continuous mental health support across all phases. TB care should integrate depression screening, stigma reduction strategies, and enhanced counseling to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.